Prediction of Hepatitis C Recurrence in Liver Transplant Recipients

Northwestern University logo

Northwestern University




Hepatitis C, Chronic
Complication of Transplanted Liver

Study type


Funder types



STU12442 1963-002

Details and patient eligibility


The purpose of the study is to look at cells of the immune system to see if the cells are different among people with different risk factors that have received a liver transplant. We will enroll 50 patients receiving liver transplant and their donors. Both donor and recipient must participate in the order for the recipient to participate in the study. We will take blood samples from these patients and their donors.

Full description

To establish whether in-vitro donor-specific immune reactivity patterns can differentiate between those liver transplant recipients who are positive for the Hepatitis C virus (HCV) who are at high risk and those who are at low risk for graft loss secondary to early recurrence of HCV. An assessment of the recipient's donor-specific immune status can be achieved by measuring T-cell activity, specifically alloreactive primed (donor-specific) T cell activity. It has been shown that detection of IFN-y in short-term enzyme-linked-immunosorbent-spot (ELISPOT) assay is consistent with the presence of primed memory T cells (6). In the transplantation setting, T cells of an allograft recipient that secret IFN-y after short in-vitro exposure to donor cells represent a prior sensitization of recipient to donor antigens in vivo. Clinically interpreted - this priming event may signify the presence of an up-coming, or an on-going, rejection episode. Our limited preliminary data suggest an additional potential clinical value for the in-vitro assessment of donor-specific IFN-y production in predicting those liver transplant recipients at higher risk for recurrence of Hepatitis C.


24 patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • Patients must be >18 years of age
  • Chronic HCV infection (and cirrhosis) - group 1
  • HCV RNA positive pre-transplant - group 1
  • Liver cirrhosis not due to HCV infection - group 2

Exclusion criteria

  • All patients < than 18 years of age
  • Patients with hepatitis C infection
  • Candidates receiving multi-organ combined transplantation
  • Patients who have received a previous liver transplantation
  • Patients who are unable to understand English

Trial design

24 participants in 2 patient groups

Group 1: HCV Positive
50 patients whom are HCV positive
Group 2: HCV Negative
50 patients whom are HCV negative.

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems